Scilex Holding Co.
- SCLX ยท Nasdaq
- Biological Products, (No Diagnostic Substances)
- Palo Alto, CA
- 34 employees
- CIK 0001820190
Updated from SEC filings through
Top things to know
Executives
- Henry Ji Exec Chair, CEO and President 4, 2026-04-20
- Stephen Hoi Ma CFO, COO and Secretary 4, 2026-04-20
- Stephen Ma Chief Financial Officer 10-K, 2026-04-10
Scilex Holding Co is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Palo Alto, CA. It trades as SCLX on Nasdaq. Revenue was $30.3M in the fiscal year ending December 31, 2025, -46.5% from the year before. It reported about 34 employees. Henry Ji is Exec Chair, CEO and President.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $30.3M 10-K, 2026-04-10 | $56.6M 10-K, 2026-04-10 | $46.7M 10-K, 2025-03-31 | $38.0M 10-K, 2024-03-12 | $31.3M 10-K, 2024-03-12 |
| Operating income | -$346M 10-K, 2026-04-10 | -$83.4M 10-K, 2026-04-10 | -$105M 10-K, 2025-03-31 | -$50.6M 10-K, 2024-03-12 | -$35.8M 10-K, 2024-03-12 |
| SG&A | $267M 10-K, 2026-04-10 | $119M 10-K, 2026-04-10 | $120M 10-K, 2025-03-31 | $64.9M 10-K, 2024-03-12 | $50.6M 10-K, 2024-03-12 |
| Net income | -$374M 10-K, 2026-04-10 | -$72.8M 10-K, 2026-04-10 | -$114M 10-K, 2025-03-31 | -$23.4M 10-K, 2024-03-12 | -$88.4M 10-K, 2024-03-12 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Henry Ji | Exec Chair, CEO and President | 4, 2026-04-20 |
| Stephen Hoi Ma | CFO, COO and Secretary | 4, 2026-04-20 |
| Stephen Ma | Chief Financial Officer | 10-K, 2026-04-10 |
| Dorman Followwill | Board member (per proxy) bio: director | DEF 14A, 2026-04-30 |
| Jay Chun, M.D., Ph.D. | Board member (per proxy) bio: member of our Board | DEF 14A, 2026-04-30 |
| Yue Alexander Wu, Ph.D. | Board member (per proxy) bio: member of our Board | DEF 14A, 2026-04-30 |
What Scilex Holding Co does
We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 8.5 million (as of August 10, 2026) | 10-Q, August 14, 2026 |
|---|---|---|
| Public float | $32.4M (as of June 30, 2025) | 10-K, April 10, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 14, 2026 |
| Latest proxy statement | Meeting June 24, 2026 (filed April 30, 2026) | DEF 14A, April 30, 2026 |
| Auditor | Bpm LLP (Walnut Creek, California) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-09-29
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-08-12
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-07-22
- Item 1.01 Entry into a material definitive agreement
- Item 2.01 Completion of acquisition or disposition of assets
- 8-K filed 2026-07-06
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-29
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2026-06-24
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-11
- Item 8.01 Other events
- 8-K filed 2026-05-05
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-28
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-03-13
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Scilex Holding Co
- What does Scilex Holding Co do?
- In its own words, from Item 1 of its 10-K: "We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes."
- What is Scilex Holding Co's revenue?
- $30.3M for the fiscal year ending December 31, 2025, from its 10-K filed April 10, 2026.
- Is Scilex Holding Co profitable?
- Scilex Holding Co reported net income of -$374M for the fiscal year ending December 31, 2025.
- How many employees does Scilex Holding Co have?
- About 34 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Scilex Holding Co?
- Henry Ji, Exec Chair, CEO and President, as named in a 4 filed April 20, 2026.
- Who is the CFO of Scilex Holding Co?
- Stephen Hoi Ma, CFO, COO and Secretary, as named in a 4 filed April 20, 2026.
- Where is Scilex Holding Co headquartered?
- Palo Alto, CA.
- What is Scilex Holding Co's stock ticker?
- SCLX, SCLXW on Nasdaq.
- What industry is Scilex Holding Co in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Scilex Holding Co's website?
- scilexholding.com.
- When does Scilex Holding Co report earnings next?
- November 13, 2026. Source: pg_future_events.
- Is Scilex Holding Co a public company?
- Yes. Scilex Holding Co files with the SEC under CIK 0001820190 and trades as SCLX.
- Who audits Scilex Holding Co?
- Bpm LLP, Walnut Creek, California, as named in its latest annual report (10-K).
- How many shares of Scilex Holding Co are outstanding?
- 8.5 million shares as of August 10, 2026, from its 10-Q filed August 14, 2026.
- What is Scilex Holding Co's public float?
- $32.4M as of June 30, 2025, as reported on the cover of its 10-K filed April 10, 2026.
- How many business segments does Scilex Holding Co report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 14, 2026.
- When is Scilex Holding Co's annual shareholder meeting?
- June 24, 2026, per its proxy statement (DEF 14A) filed April 30, 2026.